Review of vaccine hesitancy: Rationale, remit and methods.

Abstract:

:Despite a wide array of safe and effective vaccines in use globally, with major impacts on health worldwide, the WHO Strategic Advisory Group of Experts (SAGE) on Immunization has been repeatedly confronted with reports of hesitancy towards accepting specific vaccines or vaccination programmes. This paper summarizes the rationale for a SAGE review of the issue of vaccine hesitancy, its impact and ways to address it, and the convening of a Vaccine Hesitancy Working Group in March 2012 to prepare for the SAGE review. It describes the methods used and mode of operations, and advances in the relatively new field of research on vaccine hesitancy. It further elaborates and references the work conducted, including a series of products, conclusions and recommendations that emerged from the SAGE review in October 2014.

journal_name

Vaccine

journal_title

Vaccine

authors

Schuster M,Eskola J,Duclos P,SAGE Working Group on Vaccine Hesitancy.

doi

10.1016/j.vaccine.2015.04.035

subject

Has Abstract

pub_date

2015-08-14 00:00:00

pages

4157-60

issue

34

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(15)00499-5

journal_volume

33

pub_type

杂志文章,评审

相关文献

VACCINE文献大全
  • Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.

    abstract::Hybrid cell vaccines of autologous tumour cells fused with allogenic dendritic cells (DC) combine the tumour's antigenicity with the immune-stimulatory capacity of mature dendritic cells and allogenic MHC class II molecules to activate T cell help and induce tumour-specific cytotoxic T cells. This concept was tested i...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.vaccine.2005.01.081

    authors: Trefzer U,Herberth G,Wohlan K,Milling A,Thiemann M,Sharav T,Sparbier K,Sterry W,Walden P

    更新日期:2005-03-18 00:00:00

  • Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen.

    abstract::It has been shown recently that BCG can be used as a live recombinant vaccine to stimulate immune responses. Proliferative or cytotoxic T-cell responses against several viral proteins such as HIV Gag, Env or Nef were obtained after parenteral immunization with BCG expressing these proteins. Antibody responses were als...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(93)90096-g

    authors: Lagranderie M,Murray A,Gicquel B,Leclerc C,Gheorghiu M

    更新日期:1993-10-01 00:00:00

  • The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults.

    abstract::Intranasal live attenuated influenza vaccine (LAIV) has potential for self-administration (SA) by adults and adolescents, which could save time and cost in mass vaccination settings. Participants in a study of LAIV in adults (n=4561) selected either SA or health care provider (HCP) administration and were followed for...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2012.12.028

    authors: Ambrose CS,Wu X

    更新日期:2013-01-30 00:00:00

  • The expanding vaccine development pipeline, 1995-2008.

    abstract::Successful launches of recently licensed vaccines contrast with pharmaceutical industry concerns about unfavorable market conditions, making the status and future of vaccine development uncertain. We assessed trends in private-sector vaccine research and development for the period 1995-2008, using a global pharmaceuti...

    journal_title:Vaccine

    pub_type: 历史文章,杂志文章,评审

    doi:10.1016/j.vaccine.2009.11.007

    authors: Davis MM,Butchart AT,Coleman MS,Singer DC,Wheeler JR,Pok A,Freed GL

    更新日期:2010-02-03 00:00:00

  • Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials.

    abstract::To provide a safer live challenge strain for use in clinical vaccine trials, a double drug sensitive strain of Leishmania major was derived using advances in gene targeting technology by stably introducing into the chromosome a modified HSV-1 thymidine kinase gene (tk), conferring increased sensitivity to ganciclovir ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.08.032

    authors: Davoudi N,Tate CA,Warburton C,Murray A,Mahboudi F,McMaster WR

    更新日期:2005-01-19 00:00:00

  • Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.

    abstract::A new 13-valent conjugated polysaccharide vaccine (PCV13) against Streptococcus pneumoniae infections, which replaced the 7-valent vaccine (PCV7) in the regional immunization programmes for newborns and children who started but not completed the 3 doses schedule of PCV7, is available in Italy since 2010. The opportuni...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.10.013

    authors: Boccalini S,Azzari C,Resti M,Valleriani C,Cortimiglia M,Tiscione E,Bechini A,Bonanni P

    更新日期:2011-11-28 00:00:00

  • Sudden infant death syndrome, attention-deficit/hyperactivity disorder and vaccines: Longitudinal population analyses.

    abstract::Concerns about a potential link between sudden infant death syndrome (SIDS), attention deficit and hyperactivity disorder (ADHD) and vaccination are unsupported by longitudinal evidence. The analyses employed a multivariate mixed-effects model analyzing data from the National Immunization Survey, School Vaccination As...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.12.065

    authors: Yang YT,Shaw J

    更新日期:2018-01-29 00:00:00

  • Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies.

    abstract::Serogroup X Neisseria meningitidis (MenX) has recently emerged as a cause of localized disease outbreaks in sub-Saharan Africa. In order to prepare for vaccine development, MenX polysaccharide (MenX PS) was purified by standard methods and analyzed for identity and structure by NMR spectroscopy. This study presents th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.07.032

    authors: Xie O,Bolgiano B,Gao F,Lockyer K,Swann C,Jones C,Delrieu I,Njanpop-Lafourcade BM,Tamekloe TA,Pollard AJ,Norheim G

    更新日期:2012-08-31 00:00:00

  • Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain.

    abstract::A nephropathogenic K2/01 strain of infectious bronchitis virus (IBV) was attenuated by 170 serial passages in embryonated chicken eggs for possible use as a future IBV vaccine strain. High-growth properties and narrow tissue tropisms (limited replication in respiratory tracts) were achieved by the adaptation process. ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.01.062

    authors: Lee HJ,Youn HN,Kwon JS,Lee YJ,Kim JH,Lee JB,Park SY,Choi IS,Song CS

    更新日期:2010-04-01 00:00:00

  • Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).

    abstract::Prostatic acid phosphatase (PAP) is a prostate tumor antigen currently being investigated as a target antigen in several human vaccine trials, some with evidence of clinical benefit. We have previously demonstrated that plasmid DNA vaccines encoding either human or rat PAP can elicit antigen-specific cellular and humo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.07.074

    authors: Johnson LE,Frye TP,Arnot AR,Marquette C,Couture LA,Gendron-Fitzpatrick A,McNeel DG

    更新日期:2006-01-16 00:00:00

  • Hepatitis B vaccination among adolescents 13-17 years, United States, 2006-2012.

    abstract:BACKGROUND:Hepatitis B (HepB) vaccination is the most effective measure to prevent HBV infection. Routine HepB vaccination was recommended for infants in 1991 and catch-up vaccination has been recommended for adolescents since in 1995. The purpose of this study is to assess HepB vaccination among adolescents 13-17 year...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.02.021

    authors: Lu PJ,Yankey D,Jeyarajah J,O'Halloran A,Elam-Evans L,Greby SM,Singleton JA,Murphy TV

    更新日期:2015-04-08 00:00:00

  • Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?

    abstract::The continued use of oral polio vaccine (OPV) poses a threat to polio virus eradication. Stopping all polio vaccination in the post-certification era is no longer considered to be a practical option. Policy makers agree that OPV use must stop immediately after certification. Therefore, the pragmatic alternative is for...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.02.008

    authors: Khan MM

    更新日期:2008-04-07 00:00:00

  • Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus.

    abstract::A choice-format, conjoint-analysis survey was developed and fielded to estimate how features of human papillomavirus (HPV) vaccines affect mothers' perceived benefit and stated vaccine uptake for daughters. Data were collected from a national sample of 307 U.S. mothers of girls aged 13-17 years who had not yet receive...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.12.024

    authors: Brown DS,Johnson FR,Poulos C,Messonnier ML

    更新日期:2010-02-17 00:00:00

  • Enhancing immune responses to inactivated porcine parvovirus oil emulsion vaccine by co-inoculating porcine transfer factor in mice.

    abstract::Inactivated porcine parvovirus (PPV) vaccines are available commercially and widely used in the breeding herds. However, inactivated PPV vaccines have deficiencies in induction of specific cellular immune response. Transfer factor (TF) is a material that obtained from the leukocytes, and is a novel immune-stimulatory ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.05.077

    authors: Wang RN,Wang YB,Geng JW,Guo DH,Liu F,Chen HY,Zhang HY,Cui BA,Wei ZY

    更新日期:2012-07-27 00:00:00

  • High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.

    abstract:PURPOSE:We conducted a cancer vaccine clinical trial with MAGE-A4 protein. Safety, clinical response, and antigen-specific immune responses were analyzed and the prognostic factors by vaccination were investigated. EXPERIMENTAL DESIGN:Twenty patients with advanced esophageal, stomach or lung cancer were administered M...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.09.002

    authors: Saito T,Wada H,Yamasaki M,Miyata H,Nishikawa H,Sato E,Kageyama S,Shiku H,Mori M,Doki Y

    更新日期:2014-10-14 00:00:00

  • Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity.

    abstract::By using a baculovirus expression system, we have successfully produced simian immunodeficiency virus (SIV)-like particles (VLPs) with high levels of biologically active SIV envelope (Env) incorporated on their surfaces. To study whether SIV VLPs represent effective mucosal immunogens, we immunized groups of mice with...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00160-3

    authors: Yao Q,Vuong V,Li M,Compans RW

    更新日期:2002-06-07 00:00:00

  • Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants.

    abstract::An effective vaccination strategy against human immunodeficiency virus type 1 (HIV-1) should include the induction of potent cellular immune responses against conserved HIV-1 antigens. We have generated five replication competent recombinant influenza viruses (rFlu/SIV Gag nos. 1-5) expressing different portions of Ga...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00781-8

    authors: Nakaya Y,Zheng H,García-Sastre A

    更新日期:2003-05-16 00:00:00

  • Reflections on the meningococcal group C infection immunisation campaign: views from the sharp end.

    abstract::In July 1999, the Department of Health launched a campaign to immunise all children aged from 0-17 years with a new vaccine giving protection against meningococcal group C infection. Following the campaign, a survey of Immunisation Co-ordinators in England was conducted to identify strengths and weaknesses of the camp...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00160-9

    authors: Lansley M,Bedford H

    更新日期:2003-06-20 00:00:00

  • Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used.

    abstract:OBJECTIVE:The objectives of this review were to identify vaccine economic evaluations that include herd immunity and describe the methodological approaches used. METHODS:We used Kim and Goldie's search strategy from a systematic review (1976-2007) of modelling approaches used in vaccine economic evaluations and additi...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2017.10.024

    authors: Nymark LS,Sharma T,Miller A,Enemark U,Griffiths UK

    更新日期:2017-12-14 00:00:00

  • Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China.

    abstract:BACKGROUND:Vaccination is recommended to prevent influenza virus infection and associated complications. This study aimed to estimate the influenza vaccine effectiveness (VE) against hospitalization in the 2015/16 season in Beijing. METHODS:Patients who were hospitalized in the 5 study hospitals between 1 Oct 2015 and...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.03.084

    authors: Zhang Y,Wu P,Feng L,Yang P,Pan Y,Feng S,Qin Y,Zheng J,Puig-Barberà J,Muscatello D,MacIntyre R,Cowling BJ,Yu H,Wang Q

    更新日期:2017-05-25 00:00:00

  • Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations.

    abstract::In response to global interest in the development of a universal influenza vaccine, the Bill & Melinda Gates Foundation, PATH, and the Global Funders Consortium for Universal Influenza Vaccine Development convened a meeting of experts (London, UK, May 2018) to assess the role of a standardized controlled human influen...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.06.053

    authors: Innis BL,Scorza FB,Blum JS,Jain VK,Aguilar AO,Post DJ,Roberts PC,Wairagkar N,White J,Bresee J

    更新日期:2019-08-14 00:00:00

  • Measles in Bolivia: A 'honeymoon period'.

    abstract:BACKGROUND:Although measles is a highly infectious disease, the live measles vaccine provides protection for over 20 years, and immunity may be lifelong. This study assessed measles seroprevalence in schoolchildren in the Cochabamba region of Bolivia. METHODS:A seroepidemiological survey of measles immunity in 5-16-ye...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.12.037

    authors: Masuet-Aumatell C,Ramon-Torrell JM,Casanova-Rituerto A,Banqué Navarro M,Dávalos Gamboa Mdel R,Montaño Rodríguez SL

    更新日期:2013-04-12 00:00:00

  • Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines.

    abstract::The authors examined whether or not cytokines in conjunction with inactivated influenza virus vaccine enhance protection from influenza virus infection in mice. Mice were infected with influenza virus A/PR/8/34 (PR/8) at 10 LD50 by nebulizer after intranasal administration of the cytokine and the vaccine. The survival...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(92)90158-g

    authors: Cao M,Sasaki O,Yamada A,Imanishi J

    更新日期:1992-01-01 00:00:00

  • RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol.

    abstract::Ricin is a plant toxin that is a CDC level B biothreat. Our recombinant ricin A chain vaccine (RiVax), which contains mutations in both known toxic sites, has no residual toxicity at doses at least 800 times the immunogenic dose. RiVax without adjuvant given intramuscularly (i.m.) protected mice against intraperitonea...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.08.018

    authors: Smallshaw JE,Richardson JA,Vitetta ES

    更新日期:2007-10-16 00:00:00

  • BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.

    abstract::The world is facing the rising emergency of SARS-CoV-2. The outbreak of COVID-19 has caused a global public health and economic crisis.Recent epidemiological studies have shown that a possible association of BCG vaccination program with decreased COVID-19-related risks, suggesting that BCG may provide protection again...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.08.045

    authors: Tomita Y,Sato R,Ikeda T,Sakagami T

    更新日期:2020-09-22 00:00:00

  • Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs.

    abstract::Evidence that influenza vaccination during pregnancy is safe and effective at preventing influenza disease in women and their children through the first months of life is increasing. Several reports of reduced risk of adverse outcomes associated with influenza vaccination have generated interest in its potential for i...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.08.041

    authors: Savitz DA,Fell DB,Ortiz JR,Bhat N

    更新日期:2015-11-25 00:00:00

  • Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis.

    abstract::Because of the serious economic and medical consequences of brucellosis, efforts are to prevent infection of domestic animals through vaccines. Many disadvantages are associated with the current Brucella melitensis Rev.1 vaccine prompting development of alternative vaccines and delivery. Escherichia coli (DH5α) was en...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.04.036

    authors: Gupta VK,Radhakrishnan G,Harms J,Splitter G

    更新日期:2012-06-08 00:00:00

  • Diarrhea hospitalization costs among children 

    abstract:BACKGROUND:Following a recommendation by the World Health Organization, Madagascar introduced rotavirus vaccine in 2014. Though national rotavirus vaccine coverage has remained <80%, rotavirus hospitalizations declined by 78%. Gavi, the Vaccine Alliance, has provided financial support for rotavirus vaccine, however the...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.09.082

    authors: Burnett E,Rahajamanana VL,Raboba JL,Weldegebriel G,Vuo Masembe Y,Mwenda JM,Parashar UD,Tate JE,Robinson AL

    更新日期:2020-11-03 00:00:00

  • Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964-1988.

    abstract::Oral poliovirus vaccine (OPV) is tested for safety by evaluation of neurovirulence in rhesus and cynomolgus macaques. After intraspinal or intrathalamic injection of varying doses of vaccine, monkeys are followed for 17-21 days, killed, and a histopathological evaluation is made of the severity of poliomyelitis lesion...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(92)90396-2

    authors: Nathanson N,Horn SD

    更新日期:1992-01-01 00:00:00

  • Effectiveness of typhoid vaccination in US travelers.

    abstract::Typhoid vaccination is recommended in the United States before travel to countries where typhoid fever is endemic, though little information is available on its effectiveness in travelers. We estimated typhoid vaccination effectiveness (VE) by comparing vaccination status in cases of typhoid fever and paratyphoid feve...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.04.055

    authors: Mahon BE,Newton AE,Mintz ED

    更新日期:2014-06-17 00:00:00